Evidence map›Paper›PMID 36532014›Full record

ArticleFrontiers in immunology2022

Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report.

Yan Zhang, Zhicai Lin, Faliang Zhang, Xiuxiu Chen, Yaping Yang, Xin Fu, Zhong Li, Yan Sun, Qijun Qian

Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05472610 (A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05472610 phase2unknown statusnot on this map

A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection, for Relapsed and Refractory (R/R) Large B-cell Lymphoma

TypeinterventionalSponsorShanghai Mengchao Cancer HospitalRan2021 to 2023Enrolled36ConditionsLarge B-cell LymphomaArmsBZ019
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yan ZhangDepartment of Oncology, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, China.
Zhicai LinClinical R&D Center, Shanghai Cell Therapy Group Corporation, Shanghai, China.
Faliang ZhangDepartment of Oncology, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, China.
Xiuxiu ChenDepartment of Oncology, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, China.
Yaping YangClinical R&D Center, Shanghai Cell Therapy Group Corporation, Shanghai, China.
Xin FuClinical R&D Center, Shanghai Cell Therapy Group Corporation, Shanghai, China.
Zhong LiClinical R&D Center, Shanghai Cell Therapy Group Corporation, Shanghai, China.
Yan SunClinical R&D Center, Shanghai Cell Therapy Group Corporation, Shanghai, China.
Qijun QianDepartment of Oncology, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, China.
Shanghai Cell Therapy Research Institute · CNShanghai Cancer Institute · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD19-directed chimeric antigen receptor (CAR) T cell therapy has been shown to achieve a considerably durable response in patients with refractory or relapsed B cell non-Hodgkin lymphomas, as seen from the results of Zuma-1, Zuma-5, and other clinical trials. Most of these CARs were generated by lentivirus or reverse adenovirus. It is rare to see CARs using non-viral vectors, such as Piggy Bac (pb), in treating lymphoma patients with active diseases. Generally, patients with a high tumor burden tend to have a higher rate of severe cytokine release syndrome (CRS) or neurological events as reported in the literature. Patients with symptomatic pleural effusions are excluded from the Zuma-1 trial because of the risk of severe CRS. We report here that a patient with relapsed follicular lymphoma with bulky disease and massive chylous ascites failed several lines of chemotherapy. After infusion of the CD19-directed pbCAR-T cells at 6 × 10 Clinical Trial Registration: https://ClinicalTrials.gov, identifier NCT05472610.

Indexed as

Chylous AscitesLymphoma, FollicularReceptors, Chimeric AntigenAntigens, CD19Cytokine Release SyndromeHumansImmunotherapy, AdoptiveAntigens, CD19Receptors, Chimeric AntigenCD-19 directedchimeric antigen receptor T cellsfollicular lymphomanon-viral gene transferPiggy Bacrelapsed

Identifiers

PMID36532014
PMCPMC9752063
OpenAlexW4311065922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.